Newron Pharmaceuticals

Overview
Price performance
Financials
Research
Sector insights
Thematics

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is sold in Europe, Japan, the United States and other territories. While generic manufacturers had notified the FDA of their intent to file generic products, Newron and its partners reached settlement agreements and resolved the legal action. Xadago is patent protected until at least December 2027.

Latest Insights

Healthcare |
Update

23.09.24

Newron Pharmaceuticals — Moving full steam towards pivotal studies

Healthcare |
Flash note

26.06.24

Newron Pharmaceuticals — Evenamide road to registration and beyond

Healthcare |
Flash note

14.05.24

Newron Pharmaceuticals — Evenamide potential for treatment of schizophrenia

Healthcare |
Flash note

01.05.24

Newron Pharmaceuticals — Evenamide notches up another win (study 008A)

Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Analyst, Healthcare

Key Management

Marco Caremi

Executive VP of Business Development
Stefan Weber

CEO

Balance Sheet

Forecast net cash (€m)

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(22.0)	(9.1)	43.7
Relative	(16.7)	(3.3)	33.7
52 week high/low	CHF11.0/CHF4.2

Financials

Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, positive results were shared from a Phase II/III trial (study 008A) in schizophrenia patients taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, a partnership deal for evenamide is expected to be secured in the coming months, ahead of an H125 launch for the subsequent, potentially pivotal, multinational Phase III TRS programme. In FY23, Newron recorded total revenue of €9.1m (up 48.6% y-o-y), primarily derived from Xadago-related royalty income.